(Reuters) - The Foster City, California-based maker of Truvada and Atripla, which combine anti-HIV drugs into a single pill, posted net income of $407.9 million, or 42 cents per share, compared to a profit of $265.2 million, or 28 cents per share, a year earlier.
Excluding items, Gilead earned 46 cents, beating analysts' average expectation of 39 cents per share, according to Reuters Estimates.
Read more at Reuters.com Market News
Excluding items, Gilead earned 46 cents, beating analysts' average expectation of 39 cents per share, according to Reuters Estimates.
Read more at Reuters.com Market News
No comments:
Post a Comment